6 Members of Congress Write to President Obama on TPP and Access to Health Care, Criticize Closed Door Negotiations
On 9 December 2013, six members of Congress sent a letter to President Obama citing concerns in the TPP regarding access to health care and affordable medicines. The six members include Representatives Jan Schakowsky (D-IL), Michael Michaud (D-ME), Rosa DeLauro (D-CT), George Miller (D-CA), Barbara Lee (D-CA) and Peter Welch (D-MA). The letter primarily addresses efforts by USTR that result in greater monopoly power and delay entry of generic medicines, and how such efforts will affect state and federal budgets. The letter notes that "we want to express our strong opposition to actions that would create new barriers to generic competition or remove pricing and formulary options that would allow the United States and other countries to lower the prices of medicines." Additionally, the letter notes that "trade negotiations conducted behind closed doors are not the places to make changes that would have such profound consequences for patients and veterans, as well as state and federal budgets."
A PDF of the letter is attached below.
Dear President Obama:
Knowing of your commitment to improving access to affordable health care in the United States and around the world, we write to ask you to ensure that the ongoing negotiations over the Trans Pacific Partnership (TPP) Agreement do not include provisions that would undermine that goal. We also write to urge that your Administration not make any final trade agreements that affect critical health issues until members of Congress and the public have been given the opportunity to review provisions and provide input on their impact.
Many of us have had the opportunity to raise our concerns about specific proposals with the United States Trade Representative (USTR) and other members of your Administration, specifically proposals relating to patents and pricing of prescription drugs. As a result of those discussions, USTR entered a period of reflection that has now ended. Although TPP negotiations have been conducted in secret, there are numerous reports that many of those very troubling proposals are back on the table.
As reported, the proposals under discussion would have profound and long-lasting consequences. Over the past several decades, much work has been done to balance the intellectual property rights of pharmaceutical companies against the rights of countries to protect the health of their populations. The result has been a series of bipartisan agreements, most recently the Bipartisan Agreement on Trade Policy reached in May 2007, the so-called May 10th agreement. The TPP proposals under consideration would move away from that agreement, benefiting the interests of brand-name pharmaceutical companies by taking away the ability and flexibility of countries -- including the United States -- to act to protect their public health interests.
The effect of data exclusivity, patent registration and procedure, enforcement and other provisions would be to delay generic competition and increase the price of medicines. We have heard from numerous NGOs working on the ground around the world that this would seriously undermine their efforts, leading to preventable illnesses and deaths. In the United States, we have been contacted by state legislators, health care organizations and consumer advocates concerned that the changes would prevent implementation of existing and new cost-control measures, including ideas that you have include din your annual budget recommendations.
At a time when we are urging states to expand Medicaid under the Affordable Care At and looking for ways to reduce the growth of Medicare spending, we believe it makes no sense to take away critical tools to lower spending growth. It is also wrong to jeopardize our Veterans Administration's ability to negotiate lower drug prices as it is stepping up efforts to respond to the needs of our Iraq and Afghanistan veterans.
Again, we want to express our strong opposition to actions that would create new barriers to generic competition or remove pricing and formulary options that would allow the United States and other countries to lower the prices of medicines. Certainly, trade negotiations conducted behind closed doors are not the place to make changes that would have such profound consequences for patients and veterans, as well as state and federal budgets.
We appreciate your attention to these issues and look forward to continuing our work together to improve health care access and affordability, at home and abroad.